Genmab — Maj 2014
-
ja
-
så gik vi over 220 igen
-
Godt at se, at FF begrænser sin upside risiko
-
Safety in mind!
-
Salgene i dag ligner svage hænder hos private danske investorer
-
Her er lidt mel til vores ibrutinib-kage: http://bloodjournal.hematologylibrary.org/content/123/12/1957.short?rss=1
-
interessant!
-
Gad vide om gazyva kan finde på at løbe ind i de samme problemer?
-
Det er muligt. Det er samme som Jan (GSK) beskrev i et af deres slideshows. Men rart at få det fra uafhængig kilde.
-
sikke en historie, det kan blive, hvis arzerra viser sig som den bedste kombo-partner....
-
en hurtig søgning på gazyva/obinutuzumab ibrutinib giver ikke rigtig noget resultat
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind